Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - Shire plc | dp37374_ex9902.htm |
| 8-K - FORM 8-K - Shire plc | dp37374_8k.htm |
| EX-99.3 - EXHIBIT 99.3 - Shire plc | dp37374_ex9903.htm |
Exhibit 99.01
|
Press Release
www.shire.com
|
 |
Director/PDMR Share Dealings
April 2, 2013 – Shire plc (LSE: SHP, NASDAQ: SHPG), (the “Company”) announces that on March 28, 2013 Ordinary Shares (“Shares”) and American Depository Shares (“ADSs”) of the Company, as set out below, had been acquired for the Non-Executive Directors, being the part of their total fees that are paid in shares for the period of service from January 1 to March 31, 2013.
|
Type of Security (1)
|
Number of Shares/ADSs
|
||
|
William Burns
|
Shares
|
255
|
|
|
Dr. Steven Gillis
|
ADSs
|
80
|
|
|
Dr. David Ginsburg
|
ADSs
|
73
|
|
|
David Kappler
|
Shares
|
302
|
|
|
Susan Kilsby
|
ADSs
|
75
|
|
|
Anne Minto
|
Shares
|
266
|
|
|
David Stout
|
ADSs
|
81
|
|
(1) One ADS is equal to three Shares
The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ respectively, at prices of £19.90 per Share and $90.00 per ADS.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
|
Investor Relations
|
||
|
Eric Rojas
|
erojas@shire.com
|
+1 781 482 0999
|
|
Sarah Elton-Farr
|
seltonfarr@shire.com
|
+44 1256 894157
|
Notes to editors
Shire enables people with life-altering conditions to lead better lives.
Through our deep understanding of patients’ needs, we develop and provide healthcare in the areas of:
|
|
·
|
Behavioral Health and Gastro Intestinal conditions
|
|
|
·
|
Rare Diseases
|
|
|
·
|
Regenerative Medicine
|
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
as well as other symptomatic conditions treated by specialist physicians.
We aspire to imagine and lead the future of healthcare, creating value for patients, physicians, policymakers, payors and our shareholders.
2